Lantern Pharma (LTRN) Other financing activities (2020 - 2024)

Lantern Pharma's (LTRN) quarterly Other financing activities came in at $11994.0 in Q3 2024, down 78.08% on a QoQ basis from $54716.0 in Q1 2024.

Lantern Pharma (LTRN) Other financing activities (2020 - 2024) Analysis & Trends

Lantern Pharma (LTRN) has 4 years of Other financing activities data on file, last reported at $11994.0 in Q3 2024.

Quarterly Other financing activities changed N/A year-over-year to $11994.0 in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $11994.0 (down 82.02% YoY) and the FY2025 annual result came in at $13442.0, down 79.85% from the prior year.
Other financing activities slipped to $11994.0 in Q3 2024, from $54716.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $299788.0 in Q1 2022 to a low of -$1.0 in Q2 2021.
A 4-year average of $79729.7 and a median of $54716.0 in 2024 frame the typical range for Other financing activities.
Annual changes were most pronounced in 2021 — Other financing activities soared 39.91% — and 2022, when it soared 312.06%.
Tracing LTRN's Other financing activities over 4 years: stood at $52000.0 in 2020, then increased by 28.57% to $66857.0 in 2021, then soared by 348.4% to $299788.0 in 2022, then plunged by 96.0% to $11994.0 in 2024.
The last three Other financing activities figures came in at $11994.0 (Q3 2024), $54716.0 (Q1 2024), and $299788.0 (Q1 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Lantern Pharma	26.05 Mn	26.05 Mn	-

Download Data